{"id":"NCT00642642","sponsor":"Castle Creek Biosciences, LLC.","briefTitle":"Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring","officialTitle":"A Phase II/III Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of Isolagen Therapy in the Treatment of Moderate to Sever Facial Acne Scarring","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2007-11","primaryCompletion":"2009-03","completion":"2009-03","firstPosted":"2008-03-25","resultsPosted":"2013-08-21","lastUpdate":"2013-08-21"},"enrollment":122,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Scarring of the Face"],"interventions":[{"type":"BIOLOGICAL","name":"Autologous Human Fibroblasts (azficel-T)","otherNames":["LAVIV"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Double blinded active","type":"EXPERIMENTAL"},{"label":"Double blinded placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM and placebo when administered to facial acne scars.","primaryOutcome":{"measure":"Evaluator Live Acne Scarring Assessment Responders","timeFrame":"Baseline (prior to first treatment) and four months after last treatment","effectByArm":[{"arm":"Autologous Fibroblasts Cheeks","deltaMin":64,"sd":null},{"arm":"Placebo Cheeks","deltaMin":46,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0109"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":7,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":122},"commonTop":["Erythema","Swelling"]}}